This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.
Cerluten
Khavinson-framework liver "bioregulator" peptide.
Aliases (2)
Overview
What is Cerluten?
Cerluten is a Khavinson-class peptide bioregulator extracted from bovine brain tissue, developed by the St. Petersburg Institute of Bioregulation. It is sold OTC in Russia/Eastern Europe as a "brain peptide" for cognitive support, neurological recovery, and anti-aging in CNS tissue.
Key Benefits
Reported support for cognitive function, recovery from cerebrovascular events, improvements in memory and concentration in aged populations (Russian clinical literature), and putative neuroprotective and anti-aging effect.
Mechanism of Action
Mixture of short bovine-brain-derived peptides hypothesized to act as tissue-specific bioregulators — penetrating neurons and modulating gene transcription to restore cognitive and neuronal function. Mechanistic detail is preliminary; evidence base is largely Khavinson-school clinical and observational work.
▸ Reconstitution Lyophilized peptide
Reconstitute lyophilized peptide with bacteriostatic water (BAC) using sterile technique. Calculator below converts vial mg + diluent mL into syringe units.
- 1 Wipe BAC water vial + peptide vial stoppers with isopropyl alcohol.
- 2 Draw the planned diluent volume into a 1 mL syringe.
- 3 Inject diluent slowly down the inside wall of the peptide vial — do NOT spray onto powder.
- 4 Swirl gently (do not shake) until fully dissolved. Solution should be clear.
- 5 Label vial with date reconstituted; refrigerate 2-8 °C.
- 6 Use within 30 days for most peptides (BPC-157 / TB-500 ~ 60 days at 4 °C).
Quality Indicators
White, fluffy cake (peptides)
Lyophilized peptide should appear as a white, fluffy "cake" filling most of the vial bottom. Indicates proper freeze-drying.
Clear solution after reconstitution
After mixing with bacteriostatic water, the solution should be crystal clear with no particles or cloudiness.
Slight clumping acceptable
Small clumps that fully dissolve with gentle swirling are normal — shipping can cause minor compaction.
Collapsed or melted powder
Powder that looks collapsed, melted, or stuck to vial sides may have been heat-damaged in transit.
Cloudy or particulate solution
Persistent cloudiness or visible particles after gentle mixing indicate degraded or contaminated material.
What to Expect
- Day 1-7Injection / administration protocol established. Tolerability check.
- Week 2-4Early onset of effect — subtle in most users, noticeable in responders.
- Week 4-8Peak benefit window for most peptide cycles.
- Week 8+Cycle decision point: continue, taper, or break.
Side Effects & Safety
- Common (>10% users): None reported. (Caveat: small sample, no controlled safety data.)
- Less common (1-10%): Mild GI discomfort.
- Rare-serious (<1% but worth knowing): Unknown. No long-term safety data Western-indexed.
- Specific watch periods: N/A — too little data to define watch periods.
References
Khavinson VKh. "Peptides and Ageing." Neuro Endocrinol Lett 2002;23 Suppl 3:11-144. **PMID: 12374906**
Foundational Khavinson framework paper covering the broad short-peptide bioregulator hypothesis under which Cerluten is positioned. Background reference; does not establish Cerluten-specific efficacy.
View StudyAnisimov VN, Khavinson VK. "Peptide bioregulation of aging: results and prospects." Biogerontology 2010;11(2):139-149. **PMID: 19830585**
Khavinson group review of peptide bioregulator long-term geroprotective effects; broad framework support, no Cerluten-specific RCT data.
View StudyLinkova NS, Drobintseva AO, Orlova OA, Kuznetsova EP, Polyakova VO, Kvetnoy IM, Khavinson VKh. "Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line." Int J Mol Sci 2022;23(7):3552. **PMID: 35408914**
In vitro mechanism work on Khavinson short peptides; broad family-level support, no Cerluten-specific in vivo translation.
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.